ADVERTISEMENT
Dr Harbeck Talks Pertuzumab Plus Trastuzumab in HR-/HER2+ Early Breast Cancer
06/07/2021
Nadia Harbeck, MD, PhD, Head of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of München, Germany, discusses the biomarker and survival results of a study examining de-escalated neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel for patients with HR-negative/HER2-positive early Breast Cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement